
Bionano Genomics, Inc.
BNGONASDAQHealthcareMedical - Instruments & Supplies
Latest quote
$1.20
−$0.01 · -0.83%
BNGO company overview
Regular session · ET · Market data may be delayed.
GoAI snapshot
AI-powered factor overview
GoAI score
Sell
Trim exposure — unfavorable risk-reward
Valuation
45
Fair Value
Momentum
39
Weakening
Sentiment
38
Bearish
Risk resilience
34
High Risk
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
AI-generated, informational only, and not investment advice.
Company profile
Company websiteBionano Genomics, Inc. focuses on providing advanced solutions for analyzing genomes. The company's flagship offering is Saphyr, a complete system that processes samples to results, enabling the analysis of structural variations in the genome using optical genome mapping. This technology is vital for deciphering genetic variations and their functional roles. The Saphyr platform includes the Saphyr instrument, a device capable of imaging single molecules; the Saphyr Chip, a disposable component equipped with nanochannel arrays for DNA linearization; and Bionano Prep Kits and DNA labeling kits, which provide essential reagents and protocols for extracting and tagging ultra-high molecular weight DNA. Furthermore, Bionano Genomics supplies Saphyr and Bionano compute servers to support its analytical operations. It also offers NxClinical, a single software system designed for the analysis and interpretation of genomic variants identified through microarray and next-generation sequencing data, serving both cytogenetics and molecular genetics applications. In addition to its product line, Bionano Genomics delivers a variety of specialized testing and laboratory services. These include: FirstStepDx PLUS: A chromosomal microarray service used to identify underlying genetic causes in individuals with autism spectrum disorder, developmental delay, and intellectual disability. Fragile X syndrome (FXS) testing services: Comprehensive diagnostic testing for FXS. NextStepDx PLUS: An exome sequencing test aimed at detecting genetic variants associated with childhood developmental disorders. EpiPanelDx PLUS: A genetic testing panel for patients experiencing seizures, infantile spasms, encephalopathy, or febrile seizures. PGx test: A pharmacogenomics test that identifies over 60 alleles across 11 genes relevant to drug response. Bionano Genomics was founded in 2003 and operates from its corporate headquarters in San Diego, California.
- Industry
- Medical - Instruments & Supplies
- Sector
- Healthcare
- Headquarters
- US
- CEO
- Albert A. Luderer
- Listed since
- Aug 21, 2018
- Employees
- 96
Market position
- Volume
- 193.21K
- 1.36× average
- Average volume
- 141.62K
- Average daily volume
- Market cap
- 13.77M USD
- Beta
- 1.62
- Market reference 1
Earnings
- EPS beat rate
- 82%
- 9 beats, 2 misses, 0 met estimates
- Average EPS surprise
- -665.83%
- 11 comparable reports
- Latest EPS result
- -0.64
- Estimate -0.67 · Beat by 4.48%
EPS: actual versus estimate
Recent quarterly results
Revenue: actual versus estimate
Recent quarterly results
Analyst ratings
Third-party consensus; not a GoAI recommendation.
Analyst price target
Average target
$46.50
3775.00% upsideRating distribution
7 ratingsRecent analyst actions
BNGO news
BNGO peers
ETFs holding BNGO
Funds reporting this stock among their holdings, ordered by reported position size.
Continue in GoAI
Research BNGOresearch.disclaimer












